宜宾那家割双眼皮手术好宜宾玻尿酸隆鼻哪哪种比较好,宜宾做鼻子的方法,宜宾矫正鼻子多少钱,宜宾怎样去除眼部的皱纹,宜宾垫完鼻子怎样消肿快,宜宾双眼皮和开眼角价格,宜宾割双眼皮手术后的照片

BEIJING, Dec. 25 (Xinhua) -- A total of 14,976 cases of medical disputes were handled by the country's emerging third-party mediation organizations, with over 80 percent of them being successfully settled, said Vice Health Minister Zhang Mao.Zhang told Xinhua recently in an exclusive interview that China has to date set up 1,358 third-party mediation organizations to settle medical disputes.The third-party mediation organizations have come into being since late 2009 which usually hire retired doctors, medical experts and lawyers to bridge the communication gaps between doctors and patients and direct patients to resort to legal means in settling medical disputes.The third-party mediation system for medical disputes is a latest reform to ease doctor-patient tension that sometimes escalate into violence.Such incidents erupted several times this year, and in an extreme case in September, a 43-year-old surgeon in Beijing Tongren Hospital was stabbed by a patient into serious injury. The attack was believed to have been triggered by a medical dispute in which the patient alleged that the surgeon had committed malpractice during an operation.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

BEIJING, Nov. 7 (Xinhuanet) -- A huge asteroid will pass closer to Earth than the moon on Tuesday, but experts say there is no cause for alarm.Asteroid 2005 YU 55 will pass about 300-thousand kilometers from the earth. The giant space rock is about 400 meters in diameter. The close encounter will occur at 23:28 Greenwich Mean Time. Computer models showing the asteroid’s path for the next 100 years show there is no chance it will hit Earth during that time.Previous studies show the asteroid is what is called a C-type asteroid that is likely made of carbon-based materials and some silicate rock.

BEIJING, Jan. 7 (Xinhua) -- The two-day National Financial Work Conference concluded Saturday, laying out development plans for the financial sector in the coming five years, according to a statement released after the meeting.Chinese Premier Wen Jiabao was present at the conference and delivered a keynote speech.Such a conference is held every five years. Similar meetings were held in 1997, 2002 and 2007.

SHENYANG, Nov. 17 (Xinhua) -- A MD-90 aircraft left the northeastern city of Shenyang for its American home on Thursday, ending the service of the last McDonnell-Douglas jet for Chinese airlines.Chinese carriers will no longer operate MD-made jets due to growing market demands, said Lu Changchun, deputy general manager with the north China branch of China Southern Airlines, which has operated the MD-90 jet for over a decade.MD-90 jets were involved in no accidents during the decade-long-service in China, so safety concerns did not lead to their retirement, Lu said, adding about 1,000 MD-90 jets are still flying around the world.Lu, however, admitted that supply of aircraft materials was affected as the production line of MD jets shrank, after McDonnell-Douglas Cooperation was merged into Boeing in 1997.MD jets were replaced mainly because Chinese airlines need new models to accommodate air travel demands fueled by the economic boom, Lu said.The north China branch of China Southern Airlines also announced Thursday the retirement of five A300-600R planes, which are replaced by A320 family jets. China Southern Airlines began flying an Airbus A380 superjumbo in China in October.China's domestic air travel market is predicted to grow 13.9 percent annually by 2014 and transport 379 million domestic air passengers, which will make the country the world's second-largest air travel market after the United States, according to a report released by the International Air Transport Association.Back in the 1990s, a Shanghai-based aircraft maker assembled two MD-90 jets in China, Lu said, adding the two jets retired this year.Change of jets model serves the strategic transformation of China Southern Airlines and meets the market demands, Lu said.Li Jiaxiang, chief of China's civil aviation administration, estimated that over 1.5 trillion yuan (235 billion U.S. dollars) will be invested in the civil aviation industry by 2015, adding about 2,000 aircraft to the country's fleet.Commercial Aircraft Corporation of China, producer of China's first self-developed jumbo jet, the C919, has announced that it will complete the design for the passenger plane in 2012. The jet is expected to take off in 2014 and put into service in 2016.